AQST vs. XERS, CHMA, SCPH, OPTN, CMRX, PRTA, ARQT, SAVA, GYRE, and INVA
Should you be buying Aquestive Therapeutics stock or one of its competitors? The main competitors of Aquestive Therapeutics include Xeris Biopharma (XERS), Chiasma (CHMA), scPharmaceuticals (SCPH), OptiNose (OPTN), Chimerix (CMRX), Prothena (PRTA), Arcutis Biotherapeutics (ARQT), Cassava Sciences (SAVA), Gyre Therapeutics (GYRE), and Innoviva (INVA). These companies are all part of the "medical" sector.
Aquestive Therapeutics (NASDAQ:AQST) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.
Aquestive Therapeutics has higher earnings, but lower revenue than Xeris Biopharma. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.
Xeris Biopharma has a net margin of -37.58% compared to Aquestive Therapeutics' net margin of -55.85%. Aquestive Therapeutics' return on equity of 0.00% beat Xeris Biopharma's return on equity.
32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 7.9% of Aquestive Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Aquestive Therapeutics received 58 more outperform votes than Xeris Biopharma when rated by MarketBeat users. However, 69.65% of users gave Xeris Biopharma an outperform vote while only 66.67% of users gave Aquestive Therapeutics an outperform vote.
Aquestive Therapeutics has a beta of 2.95, suggesting that its stock price is 195% more volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500.
In the previous week, Aquestive Therapeutics had 3 more articles in the media than Xeris Biopharma. MarketBeat recorded 4 mentions for Aquestive Therapeutics and 1 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.87 beat Aquestive Therapeutics' score of 1.11 indicating that Xeris Biopharma is being referred to more favorably in the news media.
Aquestive Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 160.59%. Xeris Biopharma has a consensus price target of $4.63, suggesting a potential upside of 139.64%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Aquestive Therapeutics is more favorable than Xeris Biopharma.
Summary
Aquestive Therapeutics beats Xeris Biopharma on 12 of the 19 factors compared between the two stocks.
Get Aquestive Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AQST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aquestive Therapeutics Competitors List
Related Companies and Tools
